Update on the treatment of narcolepsy: clinical efficacy of pitolisant
Nature and Science of Sleep, 2017 Michael W Calik1,2 1Department of Biobehavioral Health Science, 2Center for Narcolepsy, Sleep and Health Research, University of Illinois at Chicago, Chicago, IL, United States Abstract: Narcolepsy is a neurological disease that affects 1 in 2,000 ...
Calik MW
doaj +6 more sources
Comparison of modafinil and pitolisant in narcolepsy: a non-inferiority metaanalytical approach
Drugs in Context, 2020 Aim: To assess the non-inferiority of pitolisant, a new compound for the relief of excessive daytime sleepiness (EDS) and cataplexy in narcolepsy, compared with modafinil.
Philippe Lehert, Cassandra Szoeke
doaj +2 more sources
Evaluating pitolisant as a narcolepsy treatment option
Expert Opinion on Pharmacotherapy, 2020 Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed nocturnal sleep. Treatment of narcolepsy remains challenging and current therapy is strictly symptomatically based.The present manuscript is based on an extensive ...
de Biase S. +3 more
openaire +3 more sources
Orgasmolepsy in Narcolepsy Type 1 Responsive to Pitolisant: A Case Report [PDF]
Nature and Science of Sleep, 2020 Gaia Pellitteri,1,2 Pierluigi Dolso,1 Mariarosaria Valente,1,2 Gian Luigi Gigli1– 3 1Clinical Neurology Unit, Department of Neurosciences, Udine University Hospital, Udine, Italy; 2Department of Medicine (DAME), University of Udine, Udine, Italy ...
Pellitteri G +3 more
doaj +2 more sources
Exploring Polymorphism: Hydrochloride Salts of Pitolisant and Analogues [PDF]
Crystal Growth & DesignPitolisant hydrochloride is used to treat excessive daytime sleepiness in adults with narcolepsy. The drug is formulated as a crystalline solid, and a monoclinic P21 form has been claimed in patents, but little additional information about the structure and polymorphism of the compound has been published.
Jessica Patel +13 more
core +3 more sources
Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy
Drug Design, Development and Therapy, 2018 Andrea Romigi,1 Giuseppe Vitrani,1 Temistocle Lo Giudice,1 Diego Centonze,1,2 Valentina Franco3 1IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (IS), Italy; 2Department of System Medicine, University of Rome Tor Vergata Rome, Italy; 3IRCCS ...
Romigi A +4 more
doaj +2 more sources
Adjuvant Pitolisant in a Case With Early-Onset Schizophrenia
Clinical Neuropharmacology, 2021 Early-onset schizophrenia is notorious for poor prognostication and treatment refractoriness. Child/adolescent psychiatric population, by virtue of age, is at a heightened risk for cardiometabolic risk of atypical antipsychotics. Available pharmacological options are, sorely, too limited to mitigate this risk.The authors are reporting here on an ...
Ahmed, Naguy +2 more
openaire +3 more sources
Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta‐Analysis [PDF]
Neuropsychopharmacology ReportsAim Whether histamine H3 receptor antagonists (H3R‐ANTs)/inverse agonists (H3R‐IAs) provides benefit for the treatment of schizophrenia remains unclear. This meta‐analysis was conducted to address the above clinical question.
Yasufumi Nishii +4 more
doaj +2 more sources
Comparative efficacy, safety and benefit/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea: a network meta-analysisResearch in context [PDF]
EClinicalMedicineSummary: Background: Obstructive sleep apnoea (OSA) is a common chronic respiratory disease associated with a high burden of disabilities related to sleepiness and reduced quality of life.
Jean-Louis Pépin +11 more
doaj +2 more sources
Psychiatry InternationalThere is growing evidence on the use of pitolisant for the treatment of residual excessive daytime sleepiness (EDS) in adults with obstructive sleep apnea (OSA) treated with continuous positive airway pressure (CPAP). We conducted a systematic review and
Stanley Wong +8 more
doaj +2 more sources